RenaMed Biologics Inc. of Lincoln announced Tuesday that it has leased a facility in Westborough, Mass., to serve as its commercial manufacturing facility for its renal bio-replacement therapy product for acute renal failure. The company will be relocating its corporate headquarters to Westborough during 2006 and expanding development and manufacturing operations there throughout 2007.
The new facility is in excess of 100,000 square feet, and is a multi-use building located on 39 acres. The facility has clean-room infrastructure and is well-situated to the increasing operational needs of the company, RenaMed said. Construction plans are in process and facility renovations are expected to commence in the second quarter of 2006. The first employees will be in Westborough this summer.
“RenaMed Biologics has experienced significant growth over the last few years, in conjunction with very positive phase II clinical data and our recently announced partnership with Genzyme Corp.,” said Gregory Phelps, chairman and CEO of RenaMed. “We have outgrown our current facility in Lincoln and need additional space to continue our growth and the development of our renal bio-replacement therapy. The Westborough facility is uniquely situated to meet our manufacturing needs and provides the overall space we need as we advance to the next stage of our corporate and clinical development.”
RenaMed established its Lincoln operations in 2001 and will continue to operate the Lincoln development and pilot facility in support of its expanding clinical programs. In September 2005 the company entered into a joint development and commercialization program with Genzyme on its lead product to treat acute renal failure. Under this agreement RenaMed is responsible for establishing the first U.S. manufacturing facility for this product.
RenaMed is a clinical stage company focused on the development of proprietary bio-replacement therapies for critical disease states involving severely compromised kidney function.
